0.00Open0.00Pre Close0 Volume0 Open Interest49.00Strike Price0.00Turnover2033.79%IV-0.79%PremiumMay 17, 2024Expiry Date9.59Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.8932Delta0.0284Gamma3.98Leverage Ratio-24.4961Theta0.0000Rho-3.56Eff Leverage0.0006Vega
Revolution Medicines Stock Discussion
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US)$
$BeiGene(BGNE.US)$
$ACADIA Pharmaceuticals(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...
Someone just sold 25000 shares. How good they are in timing.
👀👀 breaking out
William Blair analyst Jeff Schmitt downgraded $Focus Financial Partners(FOCS.US)$ to Market Perform from Outperform after the company reached an agreement to be acquired by Clayton, Dubilier & Rice and Stone Point Capital in an all-cash transaction valued at $53 in cash per share.
Credit Suisse Upgrades Celsius Holdings to Outperform, Raises Price Target to $...
In reaction to earnings/guidance:
• $Omnicom Group(OMC.US)$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix(NFLX.US)$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial(FULT.US)$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories(ABT.US)$ +0.6% (Ab...
No comment yet